Description
The purpose of this study is to: Describe epidemiological and clinical characteristics, natural history and real-world clinical management of ATTR amyloidosis patients Characterize the safety and effectiveness of patisiran and vutrisiran as part of routine clinical practice in the real-world clinical setting Describe disease emergence/progression in pre-symptomatic carriers of a known disease-causing transthyretin (TTR) variant
